. 2017 Jul 15;56(14):1879–1884. doi: 10.2169/internalmedicine.56.7763

Table.

Clinical Features of Concurrent ATL and AML; Review of the Literature.

Patient No.	Age/ gender	Subtype of ATL	Subtype of AML	Karyotype of AML	Latent Period (m)	Preceding Oral VP-16		Other chemotherapy before AML	Survival (m)	Refs
Patient No.	Age/ gender	Subtype of ATL	Subtype of AML	Karyotype of AML	Latent Period (m)	Yes/No	dose/ period (m)	Other chemotherapy before AML	Survival (m)	Refs
1	49/M	Smoldering	M1	not evaluable	0	No	-	none	6	[5], [21]
2	64/M	Acute	M5	47,XY,+8	17	No	none	DXR, VP-16, CY, MTX	18	[5], [22]
3	37/M	Chronic	M2	46,XY,t(9;11)(p22;q23)	23	No	-	VCR, CY, DXR, THP-ADM, MCNU, VCM, VP-16, CBDCA	24	[5], [23]
4	36/F	Smoldering	M4	46, XX, t(15;17)(q22;q21)	0	No	-	none	30+	[5], [24]
5	74/F	Chronic	M4Eo	46,XY, inv(16)(p13q22)	17	Yes	nr/3	none	18	[5], [13]
6	51/M	Acute	M2	46,XY,7q-	24	Yes	20,000 mg/16	Polypharmacy including high dose VP-16	nr	[5], [14]
7	81/F	Chronic	M4	47,XX,+8,2p-,10p+	2	No	-	none	29+	[5]
8	69/M	Acute	M2	46,XY,7q-,18p+	26	No	-	CY, DXR, MCNU, THP-ADM, VP-16, CBDCA	39	[5]
9	63/F	Lymphoma	M4	46,XX,t(8;16)(p11;p13)	23	No	-	CY, DXR, VCR, MIT, MTX, VP-16	27	[5]
10	63/F	Acute	M4	46,XX,inv(9)(p11q13)c, inv(16)(p13q22)	23	Yes	nr/nr	VCR, CY, DXR, MCNU, VCM, VP-16, CBDCA, Ara-C, MTX	30	[4]
11	64/M	Acute	M2	46,XY,t(8;21)(q22;q22)	21	No	-	VCR, CY, DXR, MCNU, VCM, VP-16, CBDCA, Ara-C, MTX, MST-16	nr	[4]
12	50/F	Lymphoma	M2	46, X, t(X;10)(p11.2;p11.2), t(5;12)(q31;p13), inv(9)(p12q13)	63	Yes	10,000 mg/29	VCR, CY, DXR, MCNU, VCM, VP-16, CBDCA, Ara-C, MTX	66	[3]
Present case	61/F	Chronic	M2	46,XY,t(6;11)(q23,q27)	47	Yes	9,800 mg/41	none	58

VP-16: etoposide, VCR: vincristine, CY: cyclophosphamide, DXR: doxorubicin, MCNU: ranimustine, VDS: vindesine, CBDCA: carboplatin, Ara-C: cytarabine, MTX: methotrexate: THP-ADM: pirarubicin, MST-16: sobuzoxane, nr: not reported, m: months, refs: references